Treatment of severe IgE-mediated food allergy encompasses a strict diet and the implementation of a management plan for the case of an accidental exposure to the offending food. Oral allergen immunotherapy with mostly milk, egg, peanut have been studied extensively in the recent past and selected products are expected on the market. We present the case of a 14 year-old adolescent, who suffered many uncontrolled allergic/ anaphylactic reactions to accidental exposure to peanut. Quality of life was limited and the parents asked for additional treatment options. Off-label use of anti-IgE/omalizumab was discussed and agreed on. The following 10 years provided an event-free life with substantial improvement of quality of life due to increase of the threshold level of symptom-inducing peanut amount. This case provides evidence for the potential off-label use of anti IgE/omalizumab for cases with severe food (peanut) allergy and substantial quality of life reduction despite the fact that adherence to treatment recommendations (diet and management plan) was given.
|Titel in Übersetzung||Anti-IgE - Omalizumab as an important and permanent therapy option for severe peanut allergy|
|Seiten (von - bis)||542-547|
|Publikationsstatus||Veröffentlicht - Juli 2021|
- Anti-IgE antibodies
- Nut allergy
ASJC Scopus Sachgebiete
- Immunologie und Allergologie